Peptide LibraryGoserelin dosage in published studies and labels
These are the doses used for Goserelin in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Goserelin has FDA-approved human dosages as the ZOLADEX implant, injected under the skin of the lower abdominal wall. ZOLADEX 3.6 mg is given every 28 days for prostate cancer, endometriosis (6 months, women 18 and over), endometrial thinning before ablation (one or two implants) and advanced breast cancer in pre- and perimenopausal women. ZOLADEX 10.8 mg is given every 12 weeks for prostate cancer only.
| Human dosing established | Yes |
|---|---|
| Route | Subcutaneous implant |
| Frequency | Every 28 days (3.6 mg) or every 12 weeks (10.8 mg) |
| Duration studied | Long-term for prostate and breast cancer; 6 months for endometriosis |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — ZOLADEX 3.6 mg, prostate cancerFDA-approved label · FDA prescribing information | Men with advanced prostate cancer, or Stage T2b-T4 (B2-C) prostate cancer with flutamide and radiotherapy | 3.6 mg. For Stage B2-C, started 8 weeks before radiotherapy: either one 3.6 mg implant followed 28 days later by one 10.8 mg implant, or four 3.6 mg implants 28 days apart | Subcutaneous, anterior abdominal wall below the navel line | Every 28 days | Long-term in advanced prostate cancer | Palliative treatment of advanced prostate cancer; management of locally confined prostate cancer | ZOLADEX (goserelin implant) 3.6 mg — FDA prescribing information (TerSera), DailyMed |
| FDA label — ZOLADEX 3.6 mg, endometriosis and endometrial thinningFDA-approved label · FDA prescribing information | Women aged 18 and over with endometriosis; women having endometrial ablation for dysfunctional uterine bleeding | 3.6 mg. Endometrial thinning: one or two implants four weeks apart, with surgery at four weeks (one implant) or two to four weeks after the second | Subcutaneous, anterior abdominal wall below the navel line | Every 28 days | 6 months for endometriosis; retreatment cannot be recommended | Management of endometriosis; endometrial thinning before ablation | ZOLADEX (goserelin implant) 3.6 mg — FDA prescribing information (TerSera), DailyMed |
| FDA label — ZOLADEX 3.6 mg, advanced breast cancerFDA-approved label · FDA prescribing information | Pre- and perimenopausal women with advanced breast cancer | 3.6 mg | Subcutaneous, anterior abdominal wall below the navel line | Every 28 days | Long-term unless clinically inappropriate | Palliative treatment of advanced breast cancer | ZOLADEX (goserelin implant) 3.6 mg — FDA prescribing information (TerSera), DailyMed |
| FDA label — ZOLADEX 10.8 mg, prostate cancerFDA-approved label · FDA prescribing information | Men with advanced prostate cancer, or Stage T2b-T4 (B2-C) prostate cancer with flutamide and radiotherapy | 10.8 mg | Subcutaneous, anterior abdominal wall below the navel line | Every 12 weeks | Long-term in advanced prostate cancer | Palliative treatment of advanced prostate cancer | ZOLADEX (goserelin implant) 10.8 mg — FDA prescribing information (TerSera), DailyMed |
Where sources disagree
- The 10.8 mg implant is not indicated in women: its label says the data are insufficient to show reliable suppression of serum estradiol. Women are treated with the 3.6 mg implant only.
- The labels warn of tumor flare in the first weeks of treatment (including ureteral obstruction and spinal cord compression), hyperglycemia and diabetes, and cardiovascular disease in men. Pregnancy must be excluded before use in benign gynecological conditions.
- A third DailyMed listing for ZOLADEX 3.6 mg is a repackager's copy (A-S Medication Solutions, 2021); the TerSera labels cited here are the current ones.